0001104659-23-076710.txt : 20230630 0001104659-23-076710.hdr.sgml : 20230630 20230630082624 ACCESSION NUMBER: 0001104659-23-076710 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230630 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230630 DATE AS OF CHANGE: 20230630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Priveterra Acquisition Corp. CENTRAL INDEX KEY: 0001837607 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 853940478 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40021 FILM NUMBER: 231059592 BUSINESS ADDRESS: STREET 1: 300 SE 2ND STREET STREET 2: SUITE 600 CITY: FORT LAUDERDALE STATE: FL ZIP: 33301 BUSINESS PHONE: (407) 808-1335 MAIL ADDRESS: STREET 1: 300 SE 2ND STREET STREET 2: SUITE 600 CITY: FORT LAUDERDALE STATE: FL ZIP: 33301 8-K 1 tm2318880d7_8k.htm FORM 8-K
0001837607 false 0001837607 2023-06-30 2023-06-30 0001837607 PMGM:UnitsEachConsistingofOneShareofClassACommonStockAndOneThirdOfOneRedeemableWarrantMember 2023-06-30 2023-06-30 0001837607 us-gaap:CommonClassAMember 2023-06-30 2023-06-30 0001837607 PMGM:RedeemableWarrantsEachWarrantExercisableForOneShareOfClassACommonStockAtAnExercisePriceof11.50Member 2023-06-30 2023-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 30, 2023

 

 

PRIVETERRA ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

  

Delaware   001-40021   85-3940478

(State or other jurisdiction of incorporation or organization)

   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

300 SE 2nd Street, Suite 600  
Fort Lauderdale, Florida  33301
(Address of principal executive offices)  

(Zip Code)

  

Registrant’s telephone number, including area code: (754) 220-9229

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

x Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class   Trading Symbol(s)   Name of each exchange on
which registered
Units, each consisting of one share of Class A common stock and one-third of one redeemable warrant   PMGMU   The Nasdaq Stock Market LLC
Class A common stock, par value $0.0001 per share   PMGM   The Nasdaq Stock Market LLC
Redeemable warrants, each warrant exercisable for one share of Class A common stock at an exercise price of $11.50   PMGMW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On June 30, 2023, AEON Biopharma, Inc. (“AEON”) issued a press release announcing an arrangement of up to $125 million in funding in connection with the proposed business combination between AEON and Priveterra Acquisition Corp. (the “Company”), as further described in Priveterra’s Current Report on Form 8-K filed with the Securities and Exchange Commission on the date hereof. A copy of the press release is furnished hereto as Exhibit 99.1.

 

The information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of PMGM under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information of the information contained in this Item 7.01, including Exhibit 99.1.

 

Item 8.01. Other Events.

 

On May 12, 2023, the Company filed a definitive proxy statement (the “Definitive Proxy Statement”) for the solicitation of proxies in connection with a special meeting of the Company’s stockholders to be held on June 30, 2023 (the “Special Meeting”) to consider and vote on, among other proposals, a business combination with AEON Biopharma, Inc. (the “Business Combination Proposal”). The Business Combination Proposal is described in more detail in the Definitive Proxy Statement.

 

Additional Definitive Proxy Soliciting Materials

 

On June 30, 2023, the Company announced it plans to adjourn the Special Meeting previously scheduled to be held on Friday, June 30, 2023, at 4:00 p.m., Eastern Time, to July 3, 2023, at 4:30 p.m., Eastern Time, in order to allow additional time for the Company to engage with its stockholders, at which time the Company expects to take a vote on the stockholder proposals. Stockholders who have previously submitted their proxies or otherwise voted and who do not want to change their vote need not take any action. Stockholders as of the April 11, 2023 record date can vote, even if they have subsequently sold their shares. Stockholders who wish to withdraw their previously submitted redemption request may do so prior to the rescheduled meeting by requesting that the transfer agent return such shares prior to the Special Meeting.

 

Supplement to the Definitive Proxy Statement

 

The Company has determined to supplement the Definitive Proxy Statement as set forth below (the “Proxy Supplement”) to provide updated information about the Business Combination Proposal. There is no change to the location, the record date, redemption deadline or any of the other proposals to be acted upon at the Special Meeting.

 

 

 

 

SUPPLEMENT TO PROXY STATEMENT

OF

PRIVETERRA ACQUISITION CORP.

Dated June 30, 2023

 

The following disclosures in this Current Report on Form 8-K supplement, and should be read in conjunction with, the disclosures contained in the Company’s definitive proxy statement (the “Definitive Proxy Statement”), filed with the Securities and Exchange Commission (the “SEC”) on May 12, 2023, which in turn should be read in its entirety. To the extent the information set forth herein differs from or updates information contained in the Definitive Proxy Statement, the information set forth herein shall supersede or supplement the information in the Definitive Proxy Statement. All other information in the Definitive Proxy Statement remains unchanged.

 

As provided in the Definitive Proxy Statement, the Company is seeking shareholder approval of, among other things, a business combination with AEON Biopharma, Inc. (the “Business Combination Proposal”). The purpose of the supplemental disclosures is to provide information about the adjournment of the Special Meeting related to the Definitive Proxy Statement.

 

Terms used herein, unless otherwise defined, have the meanings set forth in the Definitive Proxy Statement.

 

Special Meeting Date

 

On June 30, 2023, the Company announced that it plans to adjourn the Special Meeting previously scheduled to be held on June 30, 2023 to 4:30 p.m. Eastern Time on July 3, 2023 (the “Adjournment”) virtually via live webcast, at which time the Company expects to take a vote on the stockholder proposals. It can be accessed by visiting www.virtualshareholdermeeting.com/PMGM2023SM.

 

Stockholders who have previously submitted their proxies or otherwise voted and who do not want to change their vote need not take any action. Stockholders as of the April 11, 2023 record date can vote, even if they have subsequently sold their shares. Stockholders who wish to withdraw their previously submitted redemption request may do so prior to the rescheduled meeting by requesting that the transfer agent return such shares prior to the Special Meeting.

 

Forward-Looking Statements

 

This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events involving, or future performance of, the Company or AEON. In some cases, you can identify forward-looking statements by terminology such as “pro forma”, “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, and AEON and its management, as the case may be, are inherently uncertain. Certain risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s final prospectus dated February 11, 2021, relating to its IPO and other risks and uncertainties indicated from time to time in the definitive proxy statement to be delivered to the Company’s stockholders and related S-4 Registration Statement, including those set forth under “Risk Factors” therein, and other documents filed to be filed with the SEC by the Company.

 

Additional Information and Where to Find It

 

The Company has filed with the SEC a definitive proxy statement (the “Proxy Statement”) in connection with the Special Meeting and, beginning on May 12, 2023, mailed the Proxy Statement and other relevant documents to its stockholders as of the April 11, 2023 record date for the Special Meeting. The Company’s stockholders and other interested persons are advised to read the Proxy Statement and any other relevant documents that have been or will be filed with the SEC in connection with the Company’s solicitation of proxies for the Special Meeting because these documents will contain important information about the Company and related matters. Stockholders may also obtain a free copy of the Proxy Statement, as well as other relevant documents that have been or will be filed with the SEC, without charge, at the SEC’s website located at www.sec.gov.

 

 

 

 

Participants in the Solicitation

 

The Company and its directors and executive officers may be considered participants in the solicitation of proxies from the Company’s stockholders in connection with the Special Meeting. Additional information regarding the identity of these potential participants and their direct or indirect interests, by security holdings or otherwise, is set forth in the Definitive Proxy Statement. You may obtain free copies of these documents using the sources indicated above.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release, dated June 30, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 30, 2023 PRIVETERRA ACQUISITION CORP.
   
  By:  /s/ Robert J. Palmisano
  Name: Robert J. Palmisano
  Title: Chairman and Chief Executive Officer

 

 

 

 EX-99.1 2 tm2318880d7_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

PRESS RELEASE

 

AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination

 

Financing represents minimum cash required to consummate the business combination and bridge AEON through key episodic migraine data readout

 

IRVINE, Calif., June 30, 2023 – AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, and Priveterra Acquisition Corp. (NASDAQ: PMGM) (“Priveterra”), a special purpose acquisition company, today announced that a total of up to $125 million in funding has been arranged in connection with the proposed business combination between AEON and Priveterra.

 

The funding includes approximately $50 million of committed financing from existing (including $20 million of previously announced financing) and new AEON investors as well as the cash remaining in Priveterra’s trust account after redemptions, and provides the capital necessary to consummate the proposed business combination under the terms of the definitive agreement between AEON and Priveterra, and would provide AEON with sufficient gross proceeds to fund the Company beyond the anticipated announcement in the second half of 2023 of topline data from the Company’s Phase 2 study of ABP-450 for the preventive treatment of episodic migraine. AEON and Priveterra anticipate the closing of the business combination in July.

 

The $125 million in funding also includes up to $75 million of potential financing from forward purchase agreements entered into by Priveterra and third-party financing providers. Please refer to Priveterra’s current report on Form 8-K, filed June 29, 2023 with the SEC, for additional information about the financing arrangements.

 

To learn more about AEON and the development of its uniquely positioned therapeutic neurotoxin, visit www.aeonbiopharma.com.

 

About ABP-450 (prabotulinumtoxinA) Injection

 

ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins that the Company believes help with the function of the active portion of the botulinum toxin. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. AEON licenses ABP-450 from Daewoong Pharmaceutical Co., which provides AEON exclusive development and distribution rights for therapeutic indications in certain territories, including the United States, Canada and the EU, among other international territories.

 

 

 

 

PRESS RELEASE

 

About AEON Biopharma

 

AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. AEON recently completed a Phase 2 study of ABP-450 for the treatment of cervical dystonia and has an ongoing Phase 2 study of ABP-450 for the treatment of both chronic and episodic migraine. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, or the FDA, Health Canada and European Medicines Agency, or EMA. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The company built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization.

 

Proposed Transaction with Priveterra Acquisition Corp.

 

On December 13, 2022, AEON and Priveterra announced entering into a definitive business combination agreement relating to a business combination that would result in AEON becoming a public company upon the closing of the proposed transaction. The Boards of Directors of both AEON and Priveterra have approved the proposed transaction, which is expected to close in July 2023, subject to approval by Priveterra’s stockholders and the satisfaction or waiver of certain other customary closing conditions. In connection with the proposed transaction, Priveterra filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission (the “SEC”) on December 27, 2022, which was declared effective on May 12, 2023.

 

Forward-Looking Statements

 

This press release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between AEON and Priveterra, including statements regarding the benefits of the proposed transaction, the anticipated timing of the proposed transaction, the products developed by AEON and the markets in which it operates, any statements about current or planned clinical trials or related milestones, any statements of expectation or belief regarding future events, potential markets, market size, or technology developments, AEON’s projected future results, and any statements of assumptions underlying any of the items mentioned. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of Priveterra’s securities, (ii) the risk that the transaction may not be completed by Priveterra’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by Priveterra, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the agreement and plan of merger by the shareholders of Priveterra and AEON, the satisfaction of the minimum trust account amount following redemptions by Priveterra’s public shareholders and the receipt of certain governmental and regulatory approvals, (iv) the lack of a third party valuation in determining whether or not to pursue the proposed transaction, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement, (vi) the effect of the announcement or pendency of the transaction on AEON’s business relationships, performance, and business generally, (vii) risks that the proposed transaction disrupts current plans of AEON and potential difficulties in AEON employee retention as a result of the proposed transaction, (viii) the outcome of any legal proceedings that may be instituted against AEON or against Priveterra related to the business combination agreement or the proposed transaction, (ix) the ability to maintain the listing of Priveterra’s securities on the NASDAQ Exchange, (x) volatility in the price of Priveterra’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which AEON plans to operate, variations in performance across competitors, changes in laws and regulations affecting AEON’s business and changes in the combined capital structure, (xi) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities, and (xii) the risk of downturns in the highly competitive pharmaceutical industry. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the registration statement on Form S-4 and proxy statement/prospectus referenced above and other documents filed by Priveterra from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and AEON and Priveterra assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither AEON nor Priveterra gives any assurance that either AEON or Priveterra will achieve its expectations.

 

 

 

 

PRESS RELEASE

 

Contacts

 

Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com

 

Source: AEON Biopharma

 

 

 

 EX-101.SCH 3 pmgm-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 pmgm-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 pmgm-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Units, each consisting of one share of Class A common stock and one-third of one redeemable warrant [Member] Common Class A [Member] Redeemable warrants, each warrant exercisable for one share of Class A common stock at an exercise price of $11.50 [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Units, each consisting of one share of Class A common stock and one-third of one redeemable warrant [Member] Redeemable warrants, each warrant exercisable for one share of Class A common stock at an exercise price of $11.50 EX-101.PRE 6 pmgm-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2318880d7_ex99-1img001.jpg GRAPHIC begin 644 tm2318880d7_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jun. 30, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 30, 2023
Entity File Number 001-40021
Entity Registrant Name PRIVETERRA ACQUISITION CORP.
Entity Central Index Key 0001837607
Entity Tax Identification Number 85-3940478
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 300 SE 2nd Street
Entity Address, Address Line Two Suite 600
Entity Address, City or Town Fort Lauderdale
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33301
City Area Code 754
Local Phone Number 220-9229
Written Communications false
Soliciting Material true
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one share of Class A common stock and one-third of one redeemable warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Units, each consisting of one share of Class A common stock and one-third of one redeemable warrant
Trading Symbol PMGMU
Security Exchange Name NASDAQ
Common Class A [Member]  
Document Information [Line Items]  
Title of 12(b) Security Class A common stock, par value $0.0001 per share
Trading Symbol PMGM
Security Exchange Name NASDAQ
Redeemable warrants, each warrant exercisable for one share of Class A common stock at an exercise price of $11.50 [Member]  
Document Information [Line Items]  
Title of 12(b) Security Redeemable warrants, each warrant exercisable for one share of Class A common stock at an exercise price of $11.50
Trading Symbol PMGMW
Security Exchange Name NASDAQ
XML 9 tm2318880d7_8k_htm.xml IDEA: XBRL DOCUMENT 0001837607 2023-06-30 2023-06-30 0001837607 PMGM:UnitsEachConsistingofOneShareofClassACommonStockAndOneThirdOfOneRedeemableWarrantMember 2023-06-30 2023-06-30 0001837607 us-gaap:CommonClassAMember 2023-06-30 2023-06-30 0001837607 PMGM:RedeemableWarrantsEachWarrantExercisableForOneShareOfClassACommonStockAtAnExercisePriceof11.50Member 2023-06-30 2023-06-30 iso4217:USD shares iso4217:USD shares 0001837607 false 8-K 2023-06-30 PRIVETERRA ACQUISITION CORP. DE 001-40021 85-3940478 300 SE 2nd Street Suite 600 Fort Lauderdale FL 33301 754 220-9229 false true false false Units, each consisting of one share of Class A common stock and one-third of one redeemable warrant PMGMU NASDAQ Class A common stock, par value $0.0001 per share PMGM NASDAQ Redeemable warrants, each warrant exercisable for one share of Class A common stock at an exercise price of $11.50 PMGMW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 4 24 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://priveterraacquisitioncorp.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2318880d7_8k.htm pmgm-20230630.xsd pmgm-20230630_def.xml pmgm-20230630_lab.xml pmgm-20230630_pre.xml tm2318880d7_ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2318880d7_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 30 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "pmgm-20230630_def.xml" ] }, "inline": { "local": [ "tm2318880d7_8k.htm" ] }, "labelLink": { "local": [ "pmgm-20230630_lab.xml" ] }, "presentationLink": { "local": [ "pmgm-20230630_pre.xml" ] }, "schema": { "local": [ "pmgm-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 2, "memberStandard": 1, "nsprefix": "PMGM", "nsuri": "http://priveterraacquisitioncorp.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2318880d7_8k.htm", "contextRef": "From2023-06-30to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://priveterraacquisitioncorp.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2318880d7_8k.htm", "contextRef": "From2023-06-30to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "PMGM_RedeemableWarrantsEachWarrantExercisableForOneShareOfClassACommonStockAtAnExercisePriceof11.50Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable warrants, each warrant exercisable for one share of Class A common stock at an exercise price of $11.50", "label": "Redeemable warrants, each warrant exercisable for one share of Class A common stock at an exercise price of $11.50 [Member]" } } }, "localname": "RedeemableWarrantsEachWarrantExercisableForOneShareOfClassACommonStockAtAnExercisePriceof11.50Member", "nsuri": "http://priveterraacquisitioncorp.com/20230630", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "PMGM_UnitsEachConsistingofOneShareofClassACommonStockAndOneThirdOfOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Units, each consisting of one share of Class A common stock and one-third of one redeemable warrant [Member]", "label": "Units, each consisting of one share of Class A common stock and one-third of one redeemable warrant [Member]" } } }, "localname": "UnitsEachConsistingofOneShareofClassACommonStockAndOneThirdOfOneRedeemableWarrantMember", "nsuri": "http://priveterraacquisitioncorp.com/20230630", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://priveterraacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001104659-23-076710-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-076710-xbrl.zip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end